BioSpace News Archive

To facilitate its goal of building an industry-leading gene therapy company focused on rare CNS diseases, Sio has made it a priority to interact with patient organizations to determine their primary objective, whether that be stability or a cure.

The company has agreed to deliver 100 million doses of the vaccines by the end of June.

Molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening genetic disorder that progresses rapidly, results in severe and largely irreversible neurological injury, and has a high infant mortality rate; median overall survival age is about four years

The COVID-19 pandemic continues to create stress and anxiety for many Canadians, particularly those who do not have ready access to their regular support networks.

Can a medical tool predict the risk of certain medications based on a patient’s genetics, and, if so, could this information lead to doctors customizing a patient’s drug therapy? The tool being studied at DHR Health Institute for Research & Development to answer these questions is Cipherome’s Xentinel® Lighthouse, and this pilot study will also evaluate the resulting savings in health-care costs.

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, announces that the first patient outside China has been successfully dosed in a Phase 1 clinical trial of the potentially first-in-class recombinant anti-CD47/PD-L1 bispecific antibody.

HitGen announced that it has entered into a drug discovery research collaboration with UPPTHERA Inc. to identify small molecule Hits against previous known-to-be undruggable targets and novel E3 ligase.

Pharmaron Beijing Co., Limited announced that it has entered into a definitive agreement to acquire Allergan Biologics Limited in Liverpool, UK, for US$118.7 million in cash from AbbVie.

InnoCare Pharma, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced that the Company appointed Dr. Sean Zhang as Chief Medical Officer.

Johnson & Johnson announced that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices has recommended the first single-shot COVID-19 vaccine, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson, for individuals 18 years of age and older under the Emergency Use Authorization issued by the U.S. Food and Drug Administration.